智擎安能得:《Genet法說筆記》智擎(4162)安能得一線胰臟癌台灣藥證申請 ...
《Genet法說筆記》智擎(4162)安能得一線胰臟癌台灣藥證申請 ...
Provide From Google
![一線胰臟癌上半年送藥證申請,智擎安能得動能可期](https://i0.wp.com/api.multiavatar.com/%E4%B8%80%E7%B7%9A%E8%83%B0%E8%87%9F%E7%99%8C%E4%B8%8A%E5%8D%8A%E5%B9%B4%E9%80%81%E8%97%A5%E8%AD%89%E7%94%B3%E8%AB%8B%EF%BC%8C%E6%99%BA%E6%93%8E%E5%AE%89%E8%83%BD%E5%BE%97%E5%8B%95%E8%83%BD%E5%8F%AF%E6%9C%9F.png?apikey=viVnb6N20jclO8)
一線胰臟癌上半年送藥證申請,智擎安能得動能可期
https://www.moneydj.com
智擎用於治療胰臟癌用藥的安能得組合療法,過去原是用於二線市場,等於是現有主流療法出現抗藥者,才會進入該藥物適用範圍。為擴大市場,該藥物開發的 ...
Provide From Google
![安能得<sup>®<sup>](https://i0.wp.com/api.multiavatar.com/%E5%AE%89%E8%83%BD%E5%BE%97%26lt%3Bsup%26gt%3B%C2%AE%26lt%3Bsup%26gt%3B+-+PharmaEngine.png?apikey=viVnb6N20jclO8)
安能得<sup>®<sup>
https://www.pharmaengine.com
Irinotecan為喜樹鹼(camptothecin)衍生物製劑,是一已被核准且廣泛用於癌症治療的細胞毒性藥物,包括大腸癌等。智擎公司希望透過奈米微脂體的技術平台,讓此藥物獲得更 ...
Provide From Google
![對手臨床失利智擎胰臟癌新藥「安能得® 」可望獨佔市場](https://i0.wp.com/api.multiavatar.com/%E5%B0%8D%E6%89%8B%E8%87%A8%E5%BA%8A%E5%A4%B1%E5%88%A9%E6%99%BA%E6%93%8E%E8%83%B0%E8%87%9F%E7%99%8C%E6%96%B0%E8%97%A5%E3%80%8C%E5%AE%89%E8%83%BD%E5%BE%97%C2%AE+%E3%80%8D%E5%8F%AF%E6%9C%9B%E7%8D%A8%E4%BD%94%E5%B8%82%E5%A0%B4.png?apikey=viVnb6N20jclO8)
對手臨床失利智擎胰臟癌新藥「安能得® 」可望獨佔市場
https://www.gbimonthly.com
智擎旗下「安能得®」(ONIVYDE®) (nal-IRI, MM-398, PEP02)於2015年10月分獲台灣及美國核准使用於轉移性胰腺癌。同年6月獲歐洲EMA接受新藥上市許可申請,目前尚在審查中。
Provide From Google
![智擎安能得用於一線胰臟癌解盲成功,市場規模將增2](https://i0.wp.com/api.multiavatar.com/%E6%99%BA%E6%93%8E%E5%AE%89%E8%83%BD%E5%BE%97%E7%94%A8%E6%96%BC%E4%B8%80%E7%B7%9A%E8%83%B0%E8%87%9F%E7%99%8C%E8%A7%A3%E7%9B%B2%E6%88%90%E5%8A%9F%EF%BC%8C%E5%B8%82%E5%A0%B4%E8%A6%8F%E6%A8%A1%E5%B0%87%E5%A2%9E2-5%E5%80%8D.png?apikey=viVnb6N20jclO8)
智擎安能得用於一線胰臟癌解盲成功,市場規模將增2
https://tw.tech.yahoo.com
智擎9日下午公告,已上市銷售、原本屬於胰腺癌二、三線用藥的安能得,挺進線治療的組合療法NALIRIFOX之全球樞紐性臨床試驗,9日公布結果達顯著臨床 ...
Provide From Google
![智擎胰臟癌新藥一線用藥有望明年上市全球銷量將成長2倍](https://i0.wp.com/api.multiavatar.com/%E6%99%BA%E6%93%8E%E8%83%B0%E8%87%9F%E7%99%8C%E6%96%B0%E8%97%A5%E4%B8%80%E7%B7%9A%E7%94%A8%E8%97%A5%E6%9C%89%E6%9C%9B%E6%98%8E%E5%B9%B4%E4%B8%8A%E5%B8%82%E5%85%A8%E7%90%83%E9%8A%B7%E9%87%8F%E5%B0%87%E6%88%90%E9%95%B72%E5%80%8D.png?apikey=viVnb6N20jclO8)
智擎胰臟癌新藥一線用藥有望明年上市全球銷量將成長2倍
https://tw.stock.yahoo.com
智擎(4162-TW) 旗下胰臟癌新藥安能得(ONIVYDE) 一線用藥三期臨床試驗去年底完成,若送件審查一切順利,有機會明年上市銷售,以目前已上市的二線用藥 ...